Purpose To report on the outcomes of immunotherapy in patients with locally advanced periorbital squamous cell carcinoma. Methods We performed a retrospective chart review of seven consecutive patients with locally advanced periorbital cutaneous squamous cell carcinoma treated with anti-PD-1 immunotherapy. Treatments and therapeutic outcomes were reviewed. Results Of the seven patients, six were treated with cemiplimab, and one was treated with pembrolizumab. Five patients were treated with immunotherapy as neoadjuvant therapy before planned surgical resection; two patients received immunotherapy for treatment of advanced recurrent lesions deemed unresectable following multiple previous excisions and radiation therapy. In all seven patients, measurable clinical and/or radiologic response was observed. Conclusions Our findings support the emerging role of anti-PD-1 immunotherapy in the management of locally advanced periorbital cutaneous squamous cell carcinoma. All data relevant to the study are included in the article or uploaded as supplemental information. Additional data, if required, is available by contacting the corresponding author.

中文翻译：

---

免疫检查点抑制剂治疗眶周鳞状细胞癌

目的 报告免疫治疗在局部晚期眶周鳞状细胞癌患者中的疗效。方法 我们对连续 7 例接受抗 PD-1 免疫疗法治疗的局部晚期眶周皮肤鳞状细胞癌患者进行了回顾性图表审查。对治疗和治疗结果进行了审查。结果 7 名患者中，6 名接受了 cemiplimab 治疗，1 名接受了 pembrolizumab 治疗。5 名患者在计划手术切除前接受了免疫治疗作为新辅助治疗；两名患者接受了免疫治疗，以治疗在多次切除和放疗后被认为无法切除的晚期复发性病变。在所有 7 名患者中，观察到可测量的临床和/或放射学反应。结论 我们的研究结果支持抗 PD-1 免疫疗法在治疗局部晚期眶周皮肤鳞状细胞癌中的新兴作用。与研究相关的所有数据都包含在文章中或作为补充信息上传。如果需要，可通过联系相应的作者获得其他数据。